Latest Capital Raising And Funding News

Narryer Metals has reported a significant new critical minerals discovery at its Rocky Gully project, revealing high-grade scandium and rare earth element mineralisation alongside successful capital raising to fund further exploration.

Stavely Minerals' latest quarterly report reveals continued exploration progress at its key Victorian and Western Australian projects, alongside a successful capital raise to fund further drilling and geophysical surveys.

Viridis Mining and Minerals has delivered a maiden Mixed Rare Earth Carbonate product with exceptional recovery rates, alongside a substantial resource upgrade at its Colossus Rare Earth Project in Brazil.

Horizon Minerals reported a $5.165 million cash outflow for Q4 2024 but bolstered its liquidity with a capital raising in January 2025, extending its runway amid ongoing exploration investments.

Redcastle Resources has kicked off an extensive 8,500-metre drilling program across its Eastern Goldfields projects, supported by a recent $3.7 million capital raise and strategic licence acquisition.

Fitzroy River Corporation's latest quarterly report reveals a dip in royalty income but highlights progress on major silver and gold projects, alongside strategic moves in energy royalties.

Leeuwin Metals Limited (ASX:LM1) has secured a transformative acquisition of the Marda Gold Project, significantly enhancing its portfolio with a high-grade gold asset in Western Australia. The company also announced a $3.25 million capital raising to fund extensive exploration across its Australian and Canadian projects.

Wia Gold Limited reports strong drilling results at its Kokoseb Gold Project in Namibia and advances exploration in Côte d'Ivoire, backed by a A$30 million capital raise to fund an expanded 2025 development program.

Orpheus Uranium Limited reports a productive December quarter marked by a successful $1.66 million capital raise, completion of a major gravity survey at Mount Douglas, and ongoing progress toward regulatory approvals for advanced uranium exploration.

Orthocell Limited has reported a third consecutive quarter of record revenue, driven by strong sales growth and strategic market expansions, including a key US FDA submission for its nerve repair product Remplir™.